Thelansis

Primary Mitochondrial Myopathy (PMM) Market Outlook Thelansis’s “Primary Mitochondrial Myopathy (PMM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Mitochondrial Myopathy (PMM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the grea...

  Primary Mitochondrial Myopathies (PMMs) are disorders that cause oxidative phosphorylation (OXPHOS) abnormalities that primarily, but not exclusively, damage skeletal muscle. Progressive external ophthalmoplegia (PEO), eyelid ptosis, exercise intolerance, and muscle weakness are the most common symptoms of myopathy that occur in mitochondrial diseases. It is a genetically defined disorder leading to defects of oxidative phosphorylation affecting predominantly, but not exclusively, lean muscle. The indications and symptoms of PMM vary, and how one of these disorders affects one individual may differ significantly from how it affects another. This is true for persons with the same condition or even people from the same family with the same genetic variant. A gene mutation causes primary mitochondrial myopathies. When a gene variant arises, the protein product may be defective, inefficient, nonexistent, or overproduced. This can affect numerous body organ systems, including the brai...